---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-197610"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:44:51.463083+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rapport RAP-219 Phase 2a positive: 85.2% achieved ≥30% LE reduction, 24% seizure freedom

## Summary
- 85.2% of patients achieved ≥30% reduction in long episodes (p<0.0001); median LE reduction 71%.
- 72% achieved ≥50% reduction in clinical seizures (p<0.0001); 24% seizure freedom; median reduction 77.8%.
- RAP-219 well tolerated: no SAEs; 78.5% of TEAEs mild; 10% discontinuation due to TEAEs.
- Company plans end-of-Phase 2 FDA meeting Q4 2025; Phase 3 pivotal trials expected Q3 2026.
- Additional programs: Phase 2 bipolar mania trial enrolling, topline H1 2027; diabetic neuropathic pain update later 2025.

## SEC filing metadata
- accession: 0001193125-25-197610
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312525197610/0001193125-25-197610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312525197610/d919002d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-197610
- JSON: https://secwatch.observer/filing/0001193125-25-197610.json
- Plain text: https://secwatch.observer/filing/0001193125-25-197610.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.